ERBB2 and cancer: Synthesized SOXs (4a–h) were further subjected to the drug-likeness, ADME, and in silico screening for their inhibitory efficacy against cancer-specific molecular markers, i.e., CD44, AKR1D1, HER-2, and EGFR.